

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANGZHOU TIGERMED CONSULTING CO., LTD.**

### **杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

**(1) PROPOSED APPOINTMENTS OF THE FIFTH SESSION OF THE BOARD,  
(2) PROPOSED APPOINTMENTS OF NON-EMPLOYEE REPRESENTATIVE  
SUPERVISOR OF THE FIFTH SESSION OF THE SUPERVISORY  
COMMITTEE  
AND  
(3) ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR OF THE  
FIFTH SESSION OF THE SUPERVISORY COMMITTEE**

#### **PROPOSED APPOINTMENT OF THE FIFTH SESSION OF THE BOARD**

The term of office of the fourth session of the Board of Hangzhou Tigermmed Consulting Co., Ltd. (the “**Company**”) is close to its expiry date. In accordance with relevant provisions of the Company Law and the Articles of Association, the Company has carried out the election of new session of the Board as follows:

On the 32nd meeting of the fourth session of the Board convened on March 28, 2023, resolutions on proposing (i) to re-elect Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wu Hao as executive Directors of the fifth session of the Board; (ii) to re-elect Dr. Yang Bo and Mr. Liu Kai Yu Kenneth as independent non-executive Directors of the fifth session of the Board; (iii) to appoint Mr. Wen Zengyu as an executive Director of the fifth session of the Board; and (iv) to appoint Mr. Zhang Wensheng as an independent non-executive Director of the fifth session of the Board were considered and approved.

Ms. Yin Zhuan, an executive Director, will retire from office after the conclusion of the AGM as she has reached China's statutory retirement age. Furthermore, as Ms. Yin Zhuan has reached China's statutory retirement age, she will not hold any other positions in the Company. Pursuant to the Rules for Independent Directors of Listed Companies of the China Securities Regulatory Commission (CSRC), the term of office of an independent director shall not exceed six consecutive years. As the 6-year term of office of Mr. Zheng Bijun as an independent non-executive Director of the Company is about to expire, he is not eligible for re-election.

Each of Ms. Yin Zhuan and Mr. Zheng Bijun has confirmed that he/she has no disagreement with the Board and there is no other matter relating to his/her retirement that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to express its sincere gratitude to Ms. Yin Zhuan and Mr. Zheng Bijun for their long-standing contributions to the Company.

Biography details of each of the Director candidates of the fifth session of the Board are set out as follows:

### Candidates for Executive Directors

**Dr. Ye Xiaoping (葉小平)**, aged 60, is the Chairman of the Board, an executive Director and co-founder of our Company. Dr. Ye was appointed as the chairman of the Board and a Director since the incorporation of our Company in September 2010 and designated as an executive Director in April 2020. From September 2010 to April 2019, Dr. Ye served as the general manager of our Company. From March 2005 to September 2010, Dr. Ye served successively as manager, director and general manager at Hangzhou Tigermed Limited, the predecessor of our Company. Dr. Ye is primarily responsible for the overall strategic planning of our Group and supervising and overseeing the management of our business. Dr. Ye is the chairman of the Strategy Development Committee of our Company. Dr. Ye possesses extensive experience in biopharmaceutical R&D and strategic planning. Dr. Ye received his doctorate in immunology degree from University of Oxford in April 2001.

Dr. Ye served as a director of Dian Diagnostics Group Co., Ltd. (迪安診斷技術集團股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code: 300244) from September 2020 to December 2022 and Coland Holdings Limited (康聯控股有限公司) (a company listed on the Taiwan Stock Exchange with stock code: 4144, but ceased to be listed on the Taiwan Stock Exchange on October 30, 2020) since December 2010. He served as an independent non-executive director of HBM Holdings Limited (和鉑醫藥控股有限公司) (a company listed on the Stock Exchange with stock code: 2142) since December 2020. From October 2011 to January 2020, Dr. Ye served as a director of Shanghai Lide Biotech Co., Ltd. (上海立迪生物技術股份有限公司) (National Equities Exchange and Quotations stock code: 838848), the shares of which ceased to be listed on the National Equities Exchange and Quotations in April 2019.

As at the date of this announcement, Dr. Ye Xiaoping directly holds 177,239,541 of our A Shares, representing 20.32% of our total issued share capital of the Company. Dr. Ye Xiaoping and Ms. Cao Xiaochun entered into the Concert Agreement on June 9, 2010 and each of them is deemed to be interested in the A Shares that the other person is interested in under section 317 of the SFO. Ms. Cao Xiaochun holds 51,661,774 of our A Shares, representing 5.92% of our total issued share capital of our Company. Therefore, Dr. Ye Xiaoping and Ms. Cao Xiaochun are deemed to be interested in a total of 228,901,315 of our A Shares, representing 30.55% of the total number of A Shares of our Company and 26.24% of our total issued share capital.

**Ms. Cao Xiaochun (曹曉春)**, aged 54, is our executive Director, co-founder and general manager. Ms. Cao was appointed as a deputy general manager in September 2010 and was later appointed as the general manager in April 2019. She was designated as an executive Director in April 2020. From September 17, 2021 to October 21, 2022, she served as the chief financial officer of the Company. From November 2010 to May 2019, Ms. Cao served as secretary to the Board of our Company. Ms. Cao served as executive director and director successively from January 2005 to September 2010 of Hangzhou Tigermed Limited, the predecessor of our Company. Ms. Cao is primarily responsible for overseeing our Group's operations and management. Ms. Cao is a member of the Remuneration and Evaluation Committee of our Company. Ms. Cao possesses extensive experience in biopharmaceutical R&D and business operations and management.

Ms. Cao received her bachelor's degree in traditional Chinese medicine and pharmacy from Zhejiang Chinese Medical University (浙江中醫藥大學) in July 1992, graduate certificate in medicine from Zhejiang University (浙江大學) in June 2003 and graduate certificate in business administration from Renmin University of China (中國人民大學) in June 2007. Ms. Cao was admitted as a licensed pharmacist in the PRC by the Office of Personnel of Zhejiang Province (浙江省人事廳) in October 2001 and a senior engineer in the PRC by the Office of Personnel of Zhejiang Province (浙江省人事廳) in December 2002.

As at the date of this announcement, Ms. Cao Xiaochun holds 51,661,774 of our A Shares, representing 5.92% of our total issued share capital of our Company. Dr. Ye Xiaoping and Ms. Cao Xiaochun entered into the Concert Agreement on June 9, 2010 and each of them is deemed to be interested in the A Shares that the other person is interested in under section 317 of the SFO. Dr. Ye Xiaoping directly holds 177,239,541 of our A Shares, representing 20.32% of our total issued share capital of the Company. Therefore, Dr. Ye Xiaoping and Ms. Cao Xiaochun are deemed to be interested in a total of 228,901,315 of our A Shares, representing 30.55% of the total number of A Shares of our Company and 26.24% of our total issued share capital.

**Mr. Wu Hao (吳灝)**, aged 55, joined the Group in January 2020 and is currently an executive Director and the co-president of our Company. Mr. Wu is a member of the Strategy Development Committee of our Company.

Mr. Wu has over 17 years of experience in the pharmaceutical industry and has extensive marketing and managerial experience. Prior to joining the Group, Mr. Wu served successively as sales manager and a product/project manager of Schering Plough Pharmaceutical Co., Ltd.\* (先靈葆雅製藥有限公司) from August 1994 to October 1999, product manager of Shanghai Roche Pharmaceutical Co., Ltd.\* (上海羅氏製藥有限公司) from October 1999 to December 2002, marketing director of Eisai China Inc.\* (衛材(中國)製藥有限公司) from January 2003 to July 2007, director of marketing and business development department of SciClone International Pharmaceutical Co., Ltd.\* (賽生國際製藥有限公司) from August 2007 to January 2009 and the general manager of Meixin Insurance Broker (Shanghai) Co., Ltd.\* (美信保險經紀(上海)有限公司) from March 2010 to January 2020. Mr. Wu Hao has been a non-executive director of Frontage Holdings Corporation since June 1, 2022.

Mr. Wu obtained his bachelor's degree in clinical medicine from Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University) in 1992 and an EMBA degree from China Europe International Business School in 2009.

**Mr. Wen Zengyu (聞增玉)**, aged 42, joined the Company in March 2010 and is currently an executive vice president and chief operating officer of the Company. Mr. Wen Zengyu has 19 years of experience in the pharmaceutical industry. Prior to joining the Group, Mr. Wen served as a statistician of APEX International Clinical Research Co., Ltd. from March 2004 to November 2004 and a senior statistician of Schering Plough Pharmaceutical Co., Ltd.\* (先靈葆雅製藥有限公司) from December 2004 to February 2010.

Mr. Wen obtained his bachelor's degree in health service management from Weifang Medical University in July 2001 and a master's degree in epidemiology and hygienic statistics from Fudan University in June 2004.

Mr. Wen served as an executive director of Hangzhou Tigermed-IntelliPV Co., Ltd., Jiaxing Tigermed Data Management Co., Ltd. and Tigermed Xinze Medical Technology (Jiaxing) Co., Ltd. (each a wholly-owned subsidiary of the Company) since July 2021, and served as an executive director of MacroStat (China) Clinical Research Co., Ltd. (a wholly-owned subsidiary of the Company) since August 2021.

## Candidates for Independent Non-executive Directors

**Dr. Yang Bo (楊波)**, aged 51, is our independent non-executive Director. Dr. Yang joined our Company in March 2014 and served as an independent non-executive Director from March 2014 to May 2015. Dr. Yang was appointed as an independent non-executive Director in April 2020. Dr. Yang is primarily responsible for providing independent opinion and judgment to the Board, thereby protecting the overall interest of our Company. Dr. Yang is the chairman of the Nomination Committee, member of the Audit Committee and member of the Strategy Development Committee of our Company. Dr. Yang has developed her entire professional career at Zhejiang University. Since October 2003, Dr. Yang has served at the Department of Pharmacology, College of Pharmaceutical Sciences of Zhejiang University (浙江大學藥學院), mainly focusing on mechanistic study and innovative drug development of new anti-tumor drugs while teaching undergraduate and graduate courses. Dr. Yang currently serves as the dean of the Sci-Tech Academy of Zhejiang University (浙江大學科學技術研究院), the dean of the Innovative Medicine Academy of Zhejiang University (Hangzhou) (浙江大學(杭州)創新醫藥研究院), and the executive vice dean of the Intelligent Innovative Drug Academy of Zhejiang University (浙江大學智能創新藥物研究院). From August 1998 to October 2000, Dr. Yang served at the College of Pharmaceutical Sciences of Zhejiang University (浙江大學藥學院) as an associate professor and lecturer, focusing on research and development of new anti-tumor drugs and reproductive health drugs while teaching undergraduate and graduate courses.

Dr. Yang received her bachelor's degree in science in July 1993 and her master's degree in medicine in July 1995 from the College of Pharmaceutical Sciences of Zhejiang University (浙江大學藥學院). She received her doctorate in pharmacology degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (中國科學院上海藥物研究所) in July 1998.

Dr. Yang has authored many publications in scientific journals with a focus on anti-cancer and anti-tumor studies. Dr. Yang is currently a vice chairman of the Professional Committee of Zhejiang Pharmacological Society (浙江省藥學會藥理專業委員會), the vice chairman of the Anti-Cancer Drugs Professional Committee of China Anti-Cancer Association (中國抗癌協會抗癌藥物專業委員會) and deputy chairman of the Pharmaceutical Education Professional Committee of the Chinese Pharmaceutical Association (中國藥學會藥學教育專業委員會).

**Mr. Liu Kai Yu Kenneth (廖啟宇)**, aged 53, is our independent non-executive Director. Mr. Liu joined our Company and was appointed as an independent non-executive Director in April 2020. Mr. Liu is primarily responsible for providing independent opinion and judgment to the Board, thereby protecting the overall interest of our Company. Mr. Liu is the chairman of the Audit Committee, member of the Remuneration and Evaluation Committee and member of the Nomination Committee of our Company. Mr. Liu served at Hong Kong Exchanges and Clearing Limited (Stock Exchange stock code: 388) from June 2004 to October 2016, with his last position as assistant vice president in IPO Transactions, Listing & Regulatory Affairs Division. Prior to that, he served at VC CEF Capital Limited (now known as VC Capital Limited) from September 2000 to May 2003, with his last position as an assistant manager in the corporate finance department. He also worked as an audit officer in the internal audit department of Kowloon-Canton Railway Corporation from January 2000 to September 2000, an assistant manager of the audit and control division of the Hong Kong branch of Banque Nationale de Paris from August 1996 to September 1997, an accountant at Ernst & Young from August 1994 to May 1996, and a junior accountant in the audit department of Kwan Wong Tan & Fong (merged with Deloitte Touche Tohmatsu in 1997) from May 1994 to August 1994. Mr. Liu has also been serving as an independent non-executive director of Sisram Medical Ltd (a company listed on the Stock Exchange with stock code: 1696) since August 2017; an independent non-executive director of Tianli Education International Holdings Limited (a company listed on the Stock Exchange with stock code: 1773) since June 2018, and an independent non-executive director of Fourace Industries Group Holdings Limited (a company listed on the Stock Exchange with stock code: 1455) since August 2020.



Mr. Liu obtained his bachelor's degree in mechanical engineering from the Imperial College of Science, Technology and Medicine of the University of London in August 1991 and a master of business administration degree in international banking and finance from the University of Birmingham in December 1998. Mr. Liu has been a member of the Hong Kong Institute of Certified Public Accountants since July 1999 and a fellow of the Association of Chartered Certified Accountants since April 2004.

**Mr. Zhang Wensheng (張文生)**, aged 58, served as a researcher and doctoral advisor of Institute of Automation, Chinese Academy of Sciences since May 2001, and currently serves as a member of the Academic Committee and the director of the major projects division in the Institute of Automation, Chinese Academy of Sciences.

Mr. Zhang has been working in the Institute of Automation, Chinese Academy of Sciences, serving as the vice dean of Suzhou Research Institute of Intelligent Manufacturing and Big Data Industry Technology (蘇州智能製造與大數據產業技術研究院) since January 2018, the director of the Joint Laboratory of Artificial Intelligence Technology for Healthcare (醫療健康人工智能技術聯合實驗室) since July 2017, the director of Joint Laboratory of Medical Big Data Pattern Mining and Applications (醫學大數據模式挖掘與應用聯合實驗室) since January 2016, the director of Joint Laboratory of Meteorological Big Data and Machine Learning (氣象大數據與機器學習聯合實驗室) since August 2015, the deputy chief engineer since May 2013, and he served as an engineer and associate professor at Zhengzhou University of Aeronautics of Ministry of Aerospace Industry from March 1991 to September 1998.

Mr. Zhang obtained his doctoral degree in pattern recognition and intelligent systems from the Institute of Automation, Chinese Academy of Sciences in March 2001.

Each of the Director candidates of the fifth session of the Board has confirmed that, saved as disclosed above: (i) he/she does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (ii) he/she has no relationship with any other Directors, Supervisors, senior management, substantial or controlling shareholders of the Company; and (iii) as at the date of this announcement, he/she does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO.

Each of the Director candidates of the fifth session of the Board has also confirmed that there is no other information in relation to his/her re-election or appointment that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his/her re-election or appointment that needs to be brought to the attention of the Shareholders.

The term of office of the fifth session of the Board shall be three years, commencing from the date when the relevant resolutions are approved at the general meeting. If appointed, each executive Director of the fifth session of the Board will not receive remuneration in respect of his/her role as an executive Director. Dr. Yang Bo and Mr. Zhang Wensheng, proposed independent non-executive Directors of the fifth session of the Board, are entitled to RMB200,000 (tax inclusive) per annum and Mr. Liu Kai Yu Kenneth, proposed independent non-executive Director of the fifth session of the Board, is entitled to RMB220,000 (tax inclusive, of which RMB20,000 is an allowance as the chairman of the Audit Committee) per annum, which is determined in accordance with the Company's remuneration policy and with reference to the level of remuneration paid by comparable companies, the time commitment of the Directors, duties and responsibilities in the Group, their qualifications and experience. All Directors are entitled to travel expenses to attend relevant meetings and events of the Company and expenses incurred in the exercise of their duties in accordance with the Articles of Association. The Company will also disclose the total remuneration received by the Directors in the annual report accordingly. After the appointment of each of the Directors of the fifth session of the Board comes into effect, the Company will enter into service contract with each of them.

In accordance with the requirements of relevant laws, regulations and the Articles of Association, the above-mentioned proposed appointments of the Directors of the fifth session of the Board are subject to the approval by the Shareholders at the general meeting.

#### **PROPOSED APPOINTMENTS OF NON-EMPLOYEE REPRESENTATIVE SUPERVISOR OF THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE**

The term of office of the fourth session of the Supervisory Committee of the Company is close to its expiry date. In accordance with relevant provisions of the Company Law and the Articles of Association, the Company has carried out the election of new session of the Supervisory Committee as follows:

On the 21st meeting of the fourth session of the Supervisory Committee convened on March 28, 2023, resolutions on the proposal of the re-election of Ms. Chen Zhimin and Mr. Zhang Binghui as non-employee representative Supervisors of the fifth session of the Supervisory Committee were considered and approved.

Biography details of each of the non-employee representative Supervisors candidates of the fifth session of the Supervisory Committee are set out as follows:

**Ms. Chen Zhimin (陳智敏)**, aged 62, is currently the Supervisor. Ms. Chen was appointed as a shareholder Supervisor in April 2020. Ms. Chen joined our Company and was appointed as an independent non-executive Director in December 2015, and resigned as an independent non-executive Director in April 2020. Ms. Chen is primarily responsible for supervision of the finances of our Group and supervision over the Directors and senior management.

Ms. Chen has served as a senior consultant of Zhejiang Tianjin Engineering Investment and Consulting Co., Ltd. (浙江天健東方工程投資諮詢有限公司), a member of the regular board of directors of Institute of Certified Public Accountants of Zhejiang Province and a vice president of Zhejiang Engineering Cost Association (浙江省建設工程造價管理協會).

Ms. Chen was the Chief Officer of Zhejiang Zhejing Asset Appraisal Institution from May 1996 to January 2000, the chairman and general manager of Zhejiang Zhejing Asset Assessment Co., Ltd (浙江浙經資產評估有限公司) from January 2000 to February 2009, the general manager of Zhejiang Tianjin Engineering Investment and Consulting Co., Ltd. from February 2009 to April 2015, an independent director of Zhejiang Jolly Pharmaceutical Co., Ltd.(浙江佐力藥業股份有限公司) from May 2015 to March 2020, a senior consultant of Zhejiang Tianjin Engineering Investment and Consulting Co., Ltd. from May 2015 to May 2018; and an independent director of Zhejiang Weixing Industrial Development Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code: 002003) from June 2016 to July 1, 2022. She currently is external director of Zhejiang Finance and Capital Investment Co., Ltd. (浙江財通資本投資有限公司), supervisor of Hangzhou Tigermed Consulting Co., Ltd., independent director of Zhejiang Canaan Technology Limited (浙江迦南科技股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code: 300412), Hangzhou Honghua Digital Technology Stock Co., Ltd. (杭州宏華數碼科技股份有限公司) (a company listed on the Shanghai Stock Exchange with stock code: 688789), Tongkun Group Co., Ltd. (桐昆集團股份有限公司)(a company listed on the Shanghai Stock Exchange with stock code: 601233) and Hang Zhou Great Star Industrial Co., Ltd. (杭州巨星科技股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code: 002444). She was a member of the 9th, 10th and 11th CPPCC of Zhejiang Province, the 11th and 12th Citizen Building Committee of Hangzhou Province (杭州市民建委員).

**Mr. Zhang Binghui (張炳輝)**, aged 60, is currently the Chairman of our Supervisory Committee. Mr. Zhang was appointed as a non-employee representative Supervisor in April 2020. Mr. Zhang served as an independent director at Hangzhou Tigermed Limited (the predecessor of our Company) and our Company from September 2010 to June 2017. Mr. Zhang is primarily responsible for supervision of the finances of our Group and supervision over the directors and senior management.

Mr. Zhang was an independent director of Zhongjiao Tongli Construction Co., Ltd. (中交通力建設股份有限公司) (the shares of which are listed on the NEEQ with stock code: 870958) from May 2015 to June 2020; was an independent director of the GI Technologies Group Co. Ltd. (吉艾科技集團股份公司) (a company listed on the Shenzhen Stock Exchange with stock code: 300309) from October 2016 to November 2021; was an independent director of Beijing Srt Education & Technology Co., Ltd. (北京尚睿通教育科技股份有限公司) (the shares of which are listed on the NEEQ with stock code: 835971) from December 2017 to December 2020; has been an independent director of Chengdu Kanghua Biological Products Co., Ltd. (成都康華生物製品股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code: 300841) since July 2018 present; has been an independent director of Suzhou Zelgen Biopharmaceuticals Co., Ltd. (蘇州澤璟生物製藥股份有限公司) (a company listed on the Shanghai Stock Exchange with stock code: 688266) since February 2019; has been an independent director of Jiangsu Asieris Pharmaceuticals Co., Ltd.(江蘇亞虹醫藥股份有限公司) (a company listed on the Shanghai Stock Exchange with stock code: 688176) since December 2020.

Mr. Zhang was a certified public accountant in Ruihua Certified Public Accountants LLP (瑞華會計師事務所) (formerly known as Crowe CPA Limited (國富浩華會計師事務所)). Mr. Zhang received his graduation certificate in economics from the Correspondence Institute of the Party School of the Central Communist Party (中央黨校函授學院) in December 1993. Mr. Zhang was admitted as a licensed senior accountant by the Shandong Human Resources Department (山東省人事廳) in December 1998. Mr. Zhang has received certificate of membership as a non-practicing member by the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) in May 2013.

Each of the non-employee representative Supervisor candidate of the fifth session of the Supervisory Committee has confirmed that, saved as disclosed above: (i) he/she does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (ii) he/she has no relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company; and (iii) as at the date of this announcement, he/she does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO.

Each of the non-employee representative Supervisor candidate of the fifth session of the Supervisory Committee has also confirmed that there is no other information in relation to his/her re-election that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his/her re-election that needs to be brought to the attention of the Shareholders.

The term of office of the non-employee representative Supervisors of the fifth session of the Supervisory Committee shall be three years, commencing from the date when the relevant resolutions are approved at the AGM. If appointed, Ms. Chen Zhimin and Mr. Zhang Binghui are entitled to remuneration of RMB80,000 (tax inclusive) per annum, which is determined in accordance with the level of remuneration paid by comparable companies, time commitment and duties of the Supervisors, the employment conditions of other positions in the Company. All Supervisors are entitled to travel expenses to attend relevant meetings and events of the Company and expenses incurred in the exercise of their duties in accordance with the Articles of Association. After the appointment of each of the non-employee representative Supervisor of the fifth session of the Supervisory Committee enters into effect, the Company will enter into service contract with each of them.

In accordance with the requirements of relevant laws, regulations and the Articles of Association, the above-mentioned proposed appointments of the non-employee representative Supervisors of the fifth session of the Supervisory Committee are still subject to the approval by the Shareholders at the general meeting.

## **ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR OF THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE**

In accordance with relevant provisions of the Company Law and the Articles of Association, the Company held a congress of workers and staff on March 27, 2023, at which Ms. Lou Wenqing (“**Ms. Lou**”) was elected as the employee representative Supervisor of the fifth session of the Supervisory Committee of the Company. Her tenure shall be three years, commencing from the date of the AGM to the expiry date of the fifth session of the Supervisory Committee of the Company.

The biographical details of Ms. Lou are set out below:

**Ms. Lou Wenqing (樓文卿)**, aged 30, is an employee representative Supervisor. Ms. Lou joined the Internal Control and Internal Audit Department of the Company in February 2022 and engaged in internal audit work, and she currently serves as the audit executive of the Company. Ms. Lou is mainly responsible for supervising the finances of our Group and exercising supervision over the directors and senior management. Ms. Lou worked in China Merchants Group\* (中財招商集團) from October 2015 to December 2016 as a risk control specialist. From December 2016 to November 2021, she served as the general manager of Hangzhou Junqing Investment Co., Ltd.\* (杭州市軍卿投資有限公司), and she served as the alliance officer of the Federation of Seaport, Land, and Airport Information Port Operators in Zhejiang Province\* (浙江省海港陸港空港信息港運營商聯合會) from December 2021 to February 2022. Ms. Lou obtained a bachelor’s degree in business administration from the School of Modern Science and Technology of China Jiliang University in June 2014 and a master’s degree in entrepreneurial management from Royal Holloway, the University of London in October 2015.

Save as disclosed above, Ms. Lou has not held any directorship in public companies, the securities of which are listed on any securities market in Hong Kong or overseas, nor taken up any other positions in the Company and/or its subsidiaries over the past three years, nor does she have any relationship with any other Directors, Supervisors, senior management, substantial or controlling shareholders of the Company. As at the date of this announcement, Ms. Lou does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

Ms. Lou does not receive remuneration for the supervisory duty, but receive remuneration based on her position in the Company.



There is no other information required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules, and the Company is not aware of any other matters that need to be brought to the attention of the Shareholders.

## **Circular**

A circular containing, among other things, further details of the proposed appointment of the fifth session of the Board and the non-employee representative Supervisors of the fifth session of the Supervisory Committee, together with the notice of the general meeting, will be despatched to the Shareholders in due course.

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“A Share(s)”	ordinary shares issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in Renminbi and are listed for trading on the Shenzhen Stock Exchange
“Annual General Meeting” or “AGM”	the 2022 annual general meeting of the Company to be held to consider and approve, among other things, the proposed appointment of the fifth session of the Board and the proposed appointments of non-employee representative Supervisor of the fifth session of the Supervisory Committee
“Articles of Association”	the articles of association of the Company, as amended from time to time
“Audit Committee”	the audit committee of the Board
“Board”	our board of Directors
“China” or “PRC”	the People’s Republic of China, which for the purpose of the announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Company Law”	the Company Law of the People’s Republic of China (《中華人民共和國公司法》)
“Company”, “our Company”	Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格醫藥科技股份有限公司), the A Shares of which are listed on the Shenzhen Stock Exchange (stock code: 300347) and the H Shares of which are listed on the Stock Exchange (stock code: 03347)
“Director(s)”	the director(s) of the Company or any one of them
“Group”	the Company and its wholly-owned subsidiaries

“H Share(s)”	ordinary share(s) in the share capital of our Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange
“HK\$”	Hong Kong dollars and cents, both are the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time)
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	comprising A Shares and H Shares
“Shareholder(s)”	holder(s) of Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisor(s)”	the supervisor(s) of the Company or any one of them
“Supervisory Committee”	our board of Supervisors
“%”	percentage

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, March 28, 2023

*As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive Directors are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.*

\* *For identification purpose only*